+ Watch VICL
on My Watchlist
The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Everyone wants to believe that when the release date for topline data in a phase III cancer trial keeps getting pushed back further and further, it means patients receiving the study drug are living longer. I guess if anyone ever actually finds the cure for cancer, the topline data won't be released until the study participants die of other causes.You might have noticed I'm a little skeptical about the prospects for Allovectin-7 in phase III. But after making about nine grand on Vical's last upward run, it pays for me to keep a close eye on this stock. And the fact is that Vical is in a fairly good position to repeat history next spring if they don't postpone the end of the trial yet again. Of course, it's way too early to buy in again for real.
Red and green?
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions